Reach Us +1-217-403-9671
The Role Of Modeling And Simulations To Better Understand, Optimize And Predict Bioequivalence | 8241
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The role of modeling and simulations to better understand, optimize and predict Bioequivalence

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Murray P. Ducharme

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

M odeling and simulations have arguably revolutionized the fi eld of clinical pharmacology, enabling clinicians, academicians and regulators to better understand the effi cacy and toxicity of drugs by linking their relationship with exposure metrics. Virtually all new drug submissions nowadays incorporate a modeling and simulation component. In contrast, modeling and simulations are oft en misunderstood and severely underutilized in the bioequivalence fi eld. Th is presentation will review the types of studies, specifi c pharmacokinetic behavior and circumstances in which modeling and simulations can help optimize bioequivalence programmes. Case examples will be shown for drugs with atypical characteristics or specifi c formulations where modeling and simulations can actually optimize the drug development process by predicting or proving bioequivalence using novel methods in a more robust scientifi c manner while decreasing the number or complexity of the clinical studies.

Murray P. Ducharme has a pharmacy degree from the University of Montreal, and a post- graduate Pharm.D. from Wayne State University. He has been with Cetero Research since 2007 where he is globally responsible for scienti fi c and regulatory affairs. His research interests have focused on the role of modeling and simulations to better understand the clinical pharmacology of drugs and optimizing the drug development process. Dr. Ducharme has been principal or sub-investigator on thousands of trials, has authored more than 150 articles, abstracts, book chapters and manuals, and has presented internationally more than 200 posters and seminars.